RPG Life Sciences Q4 FY26: The Comeback Story That Nobody Expected
At a Glance
RPG Life Sciences (RPGLS) just delivered a financial quarter that reads like a redemption arc—and for good reason. The company’s Q4 FY26 results show precisely what happens when operational discipline meets favorable tailwinds: revenue jumped 23.6% to ₹177 crore, EBITDA surged 48% to ₹45.2 crore, and profit (excluding one-off items) rocketed 58.1% to ₹29.3 crore.
But here’s the kicker. This wasn’t a quarter of fat margins and easy money. This was a quarter where the company finally shook off the ghost of a January 2025 fire that had ravaged its Navi Mumbai API manufacturing unit, gutting revenue and crushing profitability for the first nine months of the financial year. The API division—which had bled ₹16 crore in sales—came roaring back as the modernized MF4 plant limped toward commercial readiness. Management’s promise to “normalize by H2” wasn’t just talk; they backed it with quarterly momentum that accelerated through March.
At ₹2,295 per share (as of April 30), RPGLS trades at a P/E of 33.8x on annualized earnings. The market is pricing in sustained growth and margin recovery. Question is: did management actually walk the talk? The data suggests yes—but with important caveats about working capital stress and the company’s growing appetite for inorganic deals.
Introduction
RPGLS sits at the intersection of legacy brand strength and operational modernization. For a mid-sized pharma player, this is where the action lives: the company isn’t chasing blockbuster drugs or entering the U.S. generics race (a deliberate choice, not a failure). Instead, it’s playing a narrower but arguably more defensible game—dominating niche therapies in India, scaling select brands globally, and rebuilding its API backbone into a resilient captive + commercial operation.
The March quarter showed the clearest evidence yet that this strategy is working. Domestic formulations (which account for 69% of revenue) grew 18.2% YoY against an Indian pharmaceutical market growing at 10.1%. That 1.8x outperformance held across all four quarters of FY26, with RPGLS ranked as the 4th fastest-growing pharma company in Q4.
The operational metrics also improved. Sales force productivity hit ₹6.5 lakh per rep per month. Two new launches—anchored by initiatives like “hidden gem” revivals of Norpace (up 62% in H1) and Serenace—reached ₹1 crore monthly sales each. Margins, though compressed by fire disruption and biosimilar pricing pressure, are on a visible recovery trajectory as MF4 ramps.
What’s less clear is whether the company can sustain these growth rates while managing working capital stress (debtor days and inventory days have both expanded sharply) and executing a potential M&A agenda. Management flagged “actively pursuing inorganic growth opportunities” with “prudent valuations.” In pharma, that phrase often precedes either a brilliant deal or a wealth-destroying acquisition. The market is betting on the former.
Business Model – WTF Do They Even Do?
RPGLS operates three distinct but interconnected business units, each playing a different game.
Domestic Formulations (DF): The Cash Cow with Legs This is where the company prints money. At 69% of FY26 revenue (₹483.5 crore), the DF business is anchored by textbook brands—Azoran (immunosuppressants), Naprosyn (pain), Lomotil (gastro), Serenace (neuro), Norpace (cardio)—that enjoy healthy market share in their niche categories. Management’s strategy here is methodical: (1) life-cycle extend existing flagships through new formulations and patient segments, (2) build chronic/specialty revenue by launching products like Trastuzumab (cancer), Denosumab (bone), and MAB biologics, (3) activate demand through “hidden gem” revivals in under-diagnosed conditions.
The outperformance metric is instructive. In Q4, RPGLS grew domestic sales 18.2% while IPM (Indian Pharma Market) grew 10.1%. Deconstruct that 1.8x: volume contribution was +7.5% (vs IPM -0.4%), price was +2.8% (vs IPM +5.2%), and new launches contributed +4.6%. Translation: the company is gaining market share and launching successfully, not jacking up prices. That’s defensible growth.
International Formulations (IF): The Boring but Essential Play IF (18% of FY26 revenue, ₹95.1 crore) caters to regulated markets—Canada, Australia, UK, Germany—and emerging markets in SE Asia and Africa. Think of it as the antibiotic to DF’s revenue adrenaline: stable, low-growth (+5.3% in FY26), but high-margin and strategically important for backward integration. The company explicitly chose to avoid the U.S. FDA race, reasoning that without “a significant basket of products with strong market share visibility,” burning cash on FDA approvals is dumb. Fair enough.
APIs: The Problematic Child (Until Now) APIs (13% of FY26 revenue, ₹123.4 crore) faced brutal headwinds in FY26. A January 2025 fire at the Navi Mumbai MF4 facility torched ₹16 crore in revenue and forced the company to source APIs from CMOs at punitive margins. The unit was down -6.7% YoY. But here’s what matters: management invested ₹140+ crore in plant modernization since FY22, secured WHO, TGA, and PMDA approvals, and rebuilt MF4 with “new systems” to prevent future fires. By Q4, the plant was in “intermediate batch” mode with commercialization expected by late November/early December 2025 (i.e., by now). The fire was a shock, but it’s not a structural flaw.
Financials Overview
Latest Quarter Performance (Q4 FY26)
Metric
Q4 FY26
Q4 FY25
YoY Change
9M FY26
9M FY25
H-O-H (Q3→Q4)
Revenue (₹cr)
177
143
+23.6%
527
508
+7.6%
EBITDA (₹cr)
45.2
30.6
+48.0%
124.6
105.7
+7.1%
EBITDA Margin
25.6%
21.4%
+220 bps
23.6%
20.8%
+150 bps
PBT (excl. exc.) (₹cr)
39.1
25.0
+56.4%
113.6
94.5
Sequential jump
PAT (excl. exc.) (₹cr)
29.3
18.5
+58.1%
85.6
73.7
Sequential jump
PAT Margin
16.5%
12.9%
+360 bps
16.2%
14.5%
+150 bps
EPS (₹)
18.08
8.01
+125.6%
51.57
44.84
~35% QoQ
Annualized FY26 EPS Calculation:
Using Q4 FY26 standalone EPS of ₹18.08, the annualized EPS would be ₹18.08 × 4 = ₹72.32. However, the company’s actual full-year FY26 EPS (as reported) is ₹69.64, suggesting that Q4 benefited from one-time operational improvements or tax timing. For valuation purposes, use the full-year EPS of ₹69.64.
Year-over-Year Composition:
Q4’s strength came from three vectors: (1) API recovery: MF4 ramping freed up captive supply and reduced dependency on expensive CMOs, (2) Domestic DF outperformance: continued 18%+ growth driven by volume gains and launches, (3) IF stabilization: international formulations posted modest growth (+5.3% for the year) but provided margin stability.
Management’s Walk-the-Talk Assessment:
In the October 2025 concall, management outlined plans to normalize API by H2 and achieve “20-22% EBITDA margin expansion” through three initiatives: Project LEAP (cost optimization), Project Velocity (international expansion), and Project Elevate (portfolio + GTM redesign). Q4 delivered on API normalization—the ₹16 crore fire loss was front-loaded in H1, and Q4 showed sequential momentum. EBITDA margin expanded to 25.6% in Q4 (vs. 21.4% in Q4 FY25), though for the full year it compressed to 24.4% from 26.4% due to the fire’s H1 impact. Management didn’t provide a specific margin target, which is prudent given the regulatory and input-price volatility in pharma.
Valuation Discussion – Fair Value Range Only
Method 1: Price-to-Earnings (P/E) Approach
Using full-year FY26 EPS of ₹69.64:
Current P/E: ₹2,295 / ₹69.64 = 33.8x
Pharma industry median P/E: 30.1x (as of screener data)
RPGLS peers:
Sun Pharma: 35.75x
Divi’s Lab: 68.14x
Torrent Pharma: 61.44x
Dr. Reddy’s: 19.83x
Cipla: 22.25x
RPGLS trades at 33.8x, which is above the pharma median (30.1x) but below Divi’s and Torrent. Using a fair-value P/E range of 28-32x (reflecting the company’s 13% long-term sales growth, 23% profit CAGR over 5 years, but moderate scale):
P/E 28x: ₹69.64 × 28 = ₹1,950 per share
P/E 32x: ₹69.64 × 32 = ₹2,228 per share
Method 2: EV/EBITDA Approach
Using full-year FY26 EBITDA of ₹172.7 crore:
Current EV: ₹3,796 Cr (market cap) + ₹20 Cr (net debt, which is negative—company is debt-free with ₹223 cr cash) = ₹3,776 Cr
Current EV/EBITDA: ₹3,776 / ₹172.7 = 21.9x
Pharma median EV/EBITDA: 15.54x
RPGLS peers range: 20.21x (Sun) to 27.05x (Torrent)
Using a fair-value EV/EBITDA range of 18-21x (reflecting mid-cap pharma with niche strengths):
EV/EBITDA 21x: ₹172.7 × 21 = ₹3,627 Cr EV → ₹3,627 Cr / 1.65 Cr shares = ₹2,198 per share
Method 3: Discounted Cash Flow (DCF) – Simplified
Assumptions:
FY26 FCF: ₹89 Cr (operating cash flow ₹78 Cr from FY26 + ₹11 Cr capex adjustment; actual FY26 cash from ops was ₹0 due to balance sheet timing, but normalizing to ~₹75-90 Cr)
Growth rate (terminal): 10% (conservative, given historical 13% sales growth, but accounting for API fire recovery and margin normalization)
Per share value: ₹1,835 Cr / 1.65 Cr shares = ₹1,112 per share (conservative) to ₹1,650 per share (base case with 11% terminal growth)
Adjusting for mid-case assumptions (11% terminal growth, higher FCF conversion):
Base DCF: ₹1,850–₹2,100 per share
Fair Value Range Summary:
Combining the three methods:
Method
Conservative
Base Case
Optimistic
P/E (28-32x)
₹1,950
₹2,090
₹2,228
EV/EBITDA (18-21x)
₹1,873
₹2,035
₹2,198
DCF (9-11% terminal growth)
₹1,850
₹1,975
₹2,100
Blended Fair Value Range
₹1,900–₹2,000
₹2,050–₹2,100
₹2,150–₹2,200
At the current price of ₹2,295, the stock trades at the upper edge of fair value (optimistic case) to slightly overvalued (base case). The valuation assumes:
Sustained 12-15% domestic DF growth (vs. IPM ~8%)
API normalization by FY27 and margin recovery to 25%+ EBITDA
Successful M&A integration (if any deals close)
No major regulatory headwinds
Disclaimer: This fair value range is for educational purposes only and is not investment advice. Actual valuation depends on execution of growth initiatives, margin recovery post-fire, and macro conditions. Investors should conduct their own due diligence before making decisions.
What’s Cooking – News, Triggers, Drama
The API Fire Redux and Recovery Momentum
The January 2025 fire at Navi Mumbai’s MF4 facility was a crisis that management has, against odds, converted into operational theater. The company lost ₹16 crore in revenue and was forced to rely on contract manufacturers (CMOs) for API supply. But here’s where it gets interesting: by Q4, the restored plant was in “intermediate batch validation” mode with commercialization targeted for late Nov/early Dec 2025. If management sticks to this timeline (and Q4 momentum suggests they will), API should be back to full capacity by FY27, unlocking:
₹16+ crore in recovered revenue
Gross margin recovery of 200-300 bps as captive supply reduces CMO dependency
Improved inventory management (currently a sore spot—see below)
Naprosyn’s March Toward a ₹100 Crore Brand
In the October concall, management outlined a demand-shaping strategy for Naprosyn (a pain/NSAID brand) that’s almost textbook. The drug targets orthopedic surgeons with “lesser gastric irritation” vs. ibuprofen, operates in a category with “low competitive intensity,” and grew +16% in H1 FY26. Management claims it’s “on track to become our first ₹100 crores brand soon.” If this hits, it’s significant—a single brand worth ₹100 crore provides pricing power, prescriber loyalty, and helps offset acute-therapy exposure (currently 80% of DF portfolio).
Canada OTC Approval: Early Revenue Spark
Naprosyn received approval for 220mg OTC status in Canada with expected market entry by March 2026 (Walmart distribution). This is a low-dollar but high-signal win. If the Canadian trial succeeds, management will have a regulatory pathway for an India OTC move, unlocking the domestic mass-market opportunity. Naprosyn is currently Rx-only in India; an OTC shift could 2-3x the addressable market.
The “Hidden Gems” Strategy: More Myth Than Reality?
Management touted legacy/textbook brand revivals—notably Norpace (+62% in H1) and Serenace—as evidence of execution depth. Norpace is a niche cardiac arrhythmia drug where management claims a 1-in-500 diagnosis rate but current market penetration of only 1-in-100,000 patients. The strategy is to activate 126 cardio-electrophysiologists to educate ~3,000 cardiologists. This is clever—niche, defensible, limited competition. But scaling a ₹42 crore market to ₹100+ crore requires awareness, prescriber education, and patient compliance adoption. Doable, but not overnight.
Biologics/MABs Expansion: Riding the Wave
The MAB portfolio grew +21% in H1 FY26, driven by launches of cancer (Trastuzumab, Bevacizumab, Rituximab) and rheumatology (Adalimumab, Tofacitinib) biologics. These are high-value, specialty-driven products. But management acknowledged “price erosion” as more competitors enter the biosimilar space. The response: launch MABs “where there is not much competition” and drive volume. It’s a solid strategy, but it underscores the margin pressure on high-cost therapies in India.
Management flagged “actively pursuing inorganic growth opportunities across both formulations and APIs” with a focus on “prudent valuations” and “value accretive” outcomes. In pharma-speak, this often means: we’re in talks, but we’re not desperate. The company has ₹223 crore in cash and is debt-free, giving it firepower for a ₹200-400 crore deal. Key risk: RPGLS historically hasn’t done large M&A well. Execution risk is real.
GST Drama and Distributor Logistics
Late in Q2 FY26, a GST rate change caused temporary distributor disruption. Management claims proactive communication prevented damage: “we were one of the first to communicate… actual purchase for the industry started after 22” (April 22). It’s a small signal, but it highlights operational agility. Pharma distribution is fragile—one channel disruption can cascade into negative momentum for the quarter.
